Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Update on Managing Neuropathic Pain

Author(s):  McNulty Jack P, Muller George

Issue:  May/Jun 2009 - Pain Management
View All Articles in Issue

Page(s):  182-190

Update on Managing Neuropathic Pain Page 1
Update on Managing Neuropathic Pain Page 2
Update on Managing Neuropathic Pain Page 3
Update on Managing Neuropathic Pain Page 4
Update on Managing Neuropathic Pain Page 5
Update on Managing Neuropathic Pain Page 6
Update on Managing Neuropathic Pain Page 7
Update on Managing Neuropathic Pain Page 8
Update on Managing Neuropathic Pain Page 9

Download in electronic PDF format for $65

Abstract:  Severe chronic neuropathic pain, which can profoundly and negatively affect quality of life, is usually caused by damage to peripheral nerve tissue from various physical, thermal, or chemical agents and is diffi cult to relieve. Commonly used opioids are quite effective in relieving nociceptive pain, but nerves that are damaged send pain-sensing fibers into an area of the spinal cord in which there are no mu or kappa receptors to receive opioids or the endogenous endorphins that relieve pain. Clinicians who treat neuropathic pain face daunting therapeutic challenges, but specifi c analgesic agents have proven effective in relieving that excruciating discomfort. In this article, drugs that target neuropathic pain are discussed, and case reports of patients who have overcome nerve-related pain are presented. Formulations for effective analgesic preparations useful in treating neuropathic pain are included.

Related Keywords: Jack P. McNulty, MD, FACP, FAAHPM, George Muller, RPh, neuropathic pain, neuropathy, neuralgia, pain relief, pain control, analgesic, analgesia, ketamine, gabapentin, clonidine, lidocaine, methadone, Pluronic Lecithin Organogel, topical preparations, transdermal administration, formulations, opioid conversion, levorphanol, NMDA receptors, morphine, case series, lorazepam, case reports, ketoprofen, nonsteroidal anti-inflammatory drugs, NSAIDs


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Update on Managing Neuropathic Pain
McNulty Jack P
, Muller George
May/Jun 2009
Pg. 182-190

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Topical Medications for Orofacial Neuropathic Pain
Bramwell Bethany L
May/Jun 2010
Pg. 200-203

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

Levorphanol, Methadone, and the Management of Intractable Chronic Pain: An Interview with Kerry Schmidt, BA, MBA; Jack P. McNulty, MD, FACP; and George B. Muller, RPh
Vail Jane
Jan/Feb 2006
Pg. 9-11

Levorphanol for the Treatment of Severe Chronic Pain
McNulty Jack P
May/Jun 2007
Pg. 202-211

PostScription: Treatment of Chronic Pain with Methadone or Levorphanol
McNulty Jack P
Mar/Apr 2006
Pg. 159-160

Topical Ketamine 10% for Neuropathic Pain in Spinal Cord Injury Patients: An Open-Label Trial
Rabi Joseph
, Minori Joshua, Abad Hasan, Lee Ray, Gittler Michelle
Nov/Dec 2016
Pg. 517-520

Compounded Drugs of Value in Outpatient Hospice and Palliative Care Practice
McNulty John P
, Muller George
May/Jun 2014
Pg. 190-200

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions